Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

SRNE stock may be bouncing back, but given its grab bag of issues, skip out on this fading coronavirus play. The post Don't Chase the Rebound in Sorrento — It's Not Worth the Risk appeared first on InvestorPlace.

Don't Chase the Rebound in Sorrento — It's Not Worth the Risk

Sorrento Therapeutics was an early pandemic winner. But as the world closes in on multiple vaccines, SRNE stock looks to be too late.

The Shock and Awe of Sorrento Therapeutics Is Long Gone

Investors seeking a longshot coronavirus play continue to eye SRNE stock despite Sorrento Therapeutics' high risk and continued volatility. The post Hopefuls Back Sorrento Therapeutics But Time Is a Factor appeared first on InvestorPlace.

Hopefuls Back Sorrento Therapeutics But Time Is a Factor

The Covid-19 race is close to ending. It seems unlikely that Sorrento stock can pull a rabbit out of a hat with the frontrunners emerging.

Sorrento Stock Doesn't Offer Any Upside as Vaccine Frontrunners Emerge

Thanks to Sorrento Therapeutics' all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tighten, the risks multiply.

Windows of Opportunity Are Tightening for Sorrento Therapeutics

SRNE stock has tumbled as larger players have shown progress toward a vaccine. But this isn't just a vaccine play, and the story is far from over.

Don't Bail on Sorrento Therapeutics Stock Just Yet

Avoid Sorrento Therapeutics which is still burning cash with no end in sight. SRNE stock will become more diluted as the company consistently raises cash.

Avoid Sorrento Therapeutics, Which Is Still Burning Cash With No End In Sight

SAN DIEGO, Nov. 29, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), is pleased to announce that Dr. Henry Ji, Chairman and CEO, will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Sorrento to Participate in the 32nd Piper Sandler Healthcare Investor Conference

Novavax

Moderna

The Nasdaq Composite pushed further into all-time high territory Friday morning.

These 3 Coronavirus Vaccine Stocks Are Lifting the Nasdaq to New Records

Sorrento Therapeutics Inc (NASDAQ: SRNE) shares, which have been given to much volatility, are rallying sharply Friday. What Happened: SmartPharm Therapeutics, a subsidiary of Sorrento, announced a contract award by the Defense Advanced Research Projects Agency for developing a gene-encoded antibody, or Gene Mab, that would prevent as well as treat COVID-19 infection.

Sorrento Gets DARPA Contract For Up To $34M To Develop Neutralizing Antibodies For COVID-19

The biotech's COVID-19 pipeline lands a major vote of confidence.

Why Sorrento Therapeutics Stock Is Ripping Higher Today

SAN DIEGO, Nov. 27, 2020 (GLOBE NEWSWIRE) -- SmartPharm Therapeutics, Inc. (“SmartPharm”), a wholly-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), and developer of next-generation, non-viral gene therapy technologies, announced today that it has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) co-funded by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to develop a rapid countermeasure to COVID-19. The contract would provide SmartPharm up to USD $34 million for development through Phase 2 clinical studies of a gene-encoded antibody (“Gene MAb”) that could enable rapid protection from and/or treatment of SARS-CoV-2 infection and COVID-19. Sorrento will seek further funding in support of the COVID Gene MAb program toward EUA (emergency use authorization) approval and large-scale manufacturing pending successful clinical studies.

DARPA and JPEO Award Contract to SmartPharm, a Subsidiary of Sorrento, for Development of Rapid Countermeasure Against COVID-19 Using Gene-Encoded Neutralizing Antibodies

Abbott Labs

AstraZeneca

Gilead Sciences

Inovio Pharmaceuticals

Johnson & Johnson

Regeneron Pharmaceuticals

As Pfizer and Moderna take the lead in the novel coronavirus vaccine race, here's how this affects other Covid-19-related biotech stocks. The post 7 Biotech Stocks That Are Locked in the Race for a Vaccine appeared first on InvestorPlace.

7 Biotech Stocks That Are Locked in the Race for a Vaccine

In this competition, Sorrento is a different beast because it's not just working on a vaccine, it's working on Covid-19 testing, neutralizing antibodies and preventive “shields,” among other products. That's a relevant, robust pipeline, but it hasn't been enough to prevent SRNE stock from sliding 61% from its 52-week high.

Sorrento Therapeutics Hoping Better Late Than Never Works in Vaccine Competition

The biotech has multiple drugs in preclinical development.

Sorrento Therapeutics' Multifaceted Plan to Attack COVID-19

The biotech has taken a broad approach to development, but has it cost the company time?

Sorrento Therapeutics' Slow-But-Steady Approach to COVID-19

The biotech's lead vaccine is still being testing in animals.

Sorrento Therapeutics Plans to Cut Development of Its Coronavirus Vaccine if the Leaders' Vaccines Work

Sorrento may be close to commercialization of coronavirus tests -- joining many rivals.

Could Sorrento Therapeutics Be a Millionaire-Maker Stock?

The company is waiting for the FDA to authorize the start of a clinical trial testing the next-generation product.

Sorrento Therapeutics' Next-Generation COVID-19 Therapeutic Antibody

The company has two therapeutic antibodies in development.

Sorrento Therapeutics on COVID-19 Therapy Competition: "Our Antibody Is Better Than Theirs"

The company is developing tests in all three classes: antibody, molecular, and antigen tests.

Sorrento Therapeutics' CEO Henry Ji on the Status of the Company's 3 COVID-19 Tests

Its COVID-19 programs have helped the stock rally this year, but they could also be its undoing if they fall through.

Is Sorrento Therapeutics Stock a Buy?

The biotech's executives shrug off the potential for vaccines to reduce the market opportunity for its COVID-19 treatments.

How Will Sorrento Therapeutics Deal With the Added COVID-19 Competition?

The company's focus on antibodies helped it pivot into COVID-19.

Sorrento CEO Henry Ji on How the Company Got Its Start

If you'd like to wager on a company with a packed clinical pipeline featuring potential Covid-19 treatments, SRNE stock is a great choice. The post The Breakthrough for Sorrento Could Be Just Around the Corner appeared first on InvestorPlace.

News for Sorrento Therapeutics Inc Stock (SRNE)